Geode Capital Management LLC Increases Stock Holdings in Pediatrix Medical Group, Inc. (NYSE:MD)

Geode Capital Management LLC increased its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 2.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,936,751 shares of the company’s stock after purchasing an additional 45,155 shares during the period. Geode Capital Management LLC’s holdings in Pediatrix Medical Group were worth $22,452,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of MD. Rubric Capital Management LP increased its position in shares of Pediatrix Medical Group by 797.0% in the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after purchasing an additional 7,241,400 shares during the last quarter. Dana Investment Advisors Inc. grew its holdings in shares of Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after purchasing an additional 455,785 shares during the last quarter. Weiss Asset Management LP grew its holdings in shares of Pediatrix Medical Group by 50.5% in the third quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock worth $10,580,000 after purchasing an additional 306,143 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of Pediatrix Medical Group by 639.4% in the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock worth $2,192,000 after purchasing an additional 251,072 shares during the last quarter. Finally, ClariVest Asset Management LLC bought a new position in shares of Pediatrix Medical Group in the second quarter worth approximately $1,721,000. 97.71% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Pediatrix Medical Group

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the transaction, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the transaction, the director now owns 138,683 shares of the company’s stock, valued at $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Pediatrix Medical Group Stock Performance

Shares of MD stock opened at $13.49 on Friday. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -4.41, a PEG ratio of 2.00 and a beta of 1.57. The stock has a fifty day moving average of $14.29 and a 200 day moving average of $11.15. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $16.41.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. The business had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter last year, the firm posted $0.29 earnings per share. As a group, research analysts expect that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on MD shares. Truist Financial raised their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Jefferies Financial Group raised their target price on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. StockNews.com lowered Pediatrix Medical Group from a “buy” rating to a “hold” rating in a research note on Thursday, December 19th. Deutsche Bank Aktiengesellschaft raised their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Finally, UBS Group raised their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $16.42.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.